Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, RECURSION PHARMACEUTICALS, INC. reported revenue of $75M, up 26.9% year over year. Operating margin was -867.9% and net margin -863.4%, on a free-cash-flow margin of -506.5% with capital expenditure at 8.7% of revenue. Every figure is computed directly from RXRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $75M | -867.9% | -863.4% |
| FY2024 | $59M | -814.1% | -788.0% |
| FY2023 | $45M | -785.3% | -736.0% |
| FY2022 | $40M | -616.7% | -601.0% |
| FY2021 | $10M | -1795.8% | -1832.2% |
How does RXRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.